NO20071005L - Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer - Google Patents
Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancerInfo
- Publication number
- NO20071005L NO20071005L NO20071005A NO20071005A NO20071005L NO 20071005 L NO20071005 L NO 20071005L NO 20071005 A NO20071005 A NO 20071005A NO 20071005 A NO20071005 A NO 20071005A NO 20071005 L NO20071005 L NO 20071005L
- Authority
- NO
- Norway
- Prior art keywords
- cancer
- pyrimidones
- enantiomers
- prevention
- applications
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 150000008318 pyrimidones Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Foreliggende oppfinnelse angår nye forbindelser som har strukturell formel (I) og deres farmasøytiske preparater og fremgangsmåter for anvendelse derav. Disse nye forbindelsene kan anvendes for behandling eller forebygging av kreft.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60236604P | 2004-08-18 | 2004-08-18 | |
| PCT/GB2005/003207 WO2006018628A1 (en) | 2003-03-07 | 2005-08-16 | Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20071005L true NO20071005L (no) | 2007-05-16 |
Family
ID=37904998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20071005A NO20071005L (no) | 2004-08-18 | 2007-02-21 | Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20080293744A1 (no) |
| EP (1) | EP1781674A1 (no) |
| JP (1) | JP2008509977A (no) |
| KR (1) | KR20070046176A (no) |
| CN (1) | CN101027309B (no) |
| AU (1) | AU2005273705B8 (no) |
| BR (1) | BRPI0514390A (no) |
| CA (1) | CA2575188A1 (no) |
| IL (1) | IL180810A0 (no) |
| MX (1) | MX2007001953A (no) |
| MY (1) | MY141233A (no) |
| NO (1) | NO20071005L (no) |
| RU (1) | RU2447077C2 (no) |
| SA (1) | SA05260258B1 (no) |
| TW (1) | TW200616977A (no) |
| UA (1) | UA89201C2 (no) |
| UY (1) | UY29070A1 (no) |
| ZA (1) | ZA200701082B (no) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG185996A1 (en) * | 2007-11-13 | 2012-12-28 | Icos Corp | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| EP2448938B9 (en) | 2009-06-29 | 2015-06-10 | Incyte Corporation | Pyrimidinones as pi3k inhibitors |
| MX389479B (es) | 2011-09-02 | 2025-03-20 | Incyte Holdings Corp | Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k) |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3964507A1 (en) | 2013-10-04 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN106456628A (zh) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| SG10201912302VA (en) | 2015-02-27 | 2020-02-27 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| JP2025539264A (ja) * | 2022-11-10 | 2025-12-04 | リボメトリックス,インコーポレイティド | eIF4E阻害剤としての化合物及び組成物、ならびにそれらの使用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5792767A (en) | 1995-01-27 | 1998-08-11 | Abbott Laboratories | Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists |
| IL125589A0 (en) | 1996-03-11 | 1999-03-12 | Novartis Ag | Pyrimidin-4-one derivatives as pesticides |
| NZ511674A (en) | 1998-12-23 | 2003-11-28 | Du Pont Pharm Co | Nitrogen containing heterobicycles as factor Xa inhibitors |
| DE60017157T2 (de) | 1999-09-16 | 2005-12-22 | Curis, Inc., Cambridge | Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen |
| US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US7230000B1 (en) * | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
| EP1226129B1 (en) | 1999-10-27 | 2006-05-24 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| NZ526622A (en) | 2000-12-11 | 2006-07-28 | Amgen Sf Llc | CXCR3 antagonists |
| WO2002078639A2 (en) | 2001-03-29 | 2002-10-10 | Bristol-Myers Squibb Company | A method of treating proliferative diseases using eg5 inhibitors |
| US6900214B2 (en) | 2001-03-29 | 2005-05-31 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| US6809102B2 (en) * | 2001-03-29 | 2004-10-26 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| EP1383771A1 (en) | 2001-04-20 | 2004-01-28 | Vertex Pharmaceuticals Incorporated | 9-deazaguanine derivatives as inhibitors of gsk-3 |
| CA2465491A1 (en) | 2001-11-07 | 2003-05-15 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| AU2002346471A1 (en) * | 2001-11-20 | 2003-06-10 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
| JP4467979B2 (ja) * | 2001-12-06 | 2010-05-26 | メルク・シャープ・エンド・ドーム・コーポレイション | 有糸分裂キネシン阻害剤 |
| ATE372341T1 (de) | 2001-12-06 | 2007-09-15 | Merck & Co Inc | Inhibitoren von mitotischem kinesin |
| CA2467916A1 (en) * | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| WO2003050122A2 (en) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| ATE424388T1 (de) * | 2001-12-06 | 2009-03-15 | Merck & Co Inc | Mitotische kinesinhemmer |
| US7009049B2 (en) | 2002-02-15 | 2006-03-07 | Cytokinetics, Inc. | Syntheses of quinazolinones |
| JP4664597B2 (ja) * | 2002-04-17 | 2011-04-06 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
| US7166595B2 (en) * | 2002-05-09 | 2007-01-23 | Cytokinetics, Inc. | Compounds, methods and compositions |
| AU2003270015A1 (en) | 2002-05-09 | 2003-12-02 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| TW200407143A (en) | 2002-05-21 | 2004-05-16 | Bristol Myers Squibb Co | Pyrrolotriazinone compounds and their use to treat diseases |
| JP2005530806A (ja) | 2002-05-23 | 2005-10-13 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害薬 |
| WO2003103575A2 (en) | 2002-05-23 | 2003-12-18 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| EP1517904A4 (en) | 2002-05-23 | 2007-02-21 | Merck & Co Inc | INHIBITORS OF MITOTIC KINESINE |
| CA2489367A1 (en) | 2002-06-14 | 2003-12-24 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| ATE423110T1 (de) * | 2002-07-17 | 2009-03-15 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen |
| WO2004009036A2 (en) | 2002-07-23 | 2004-01-29 | Cytokinetics, Inc. | Compounds compositions and methods |
| EP1539180A4 (en) | 2002-08-21 | 2006-08-30 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| WO2004024086A2 (en) | 2002-09-13 | 2004-03-25 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2004034972A2 (en) | 2002-09-30 | 2004-04-29 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| AU2003300031A1 (en) | 2002-10-11 | 2004-05-04 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| NZ539643A (en) | 2002-10-11 | 2006-11-30 | Smithkline Beecham Corp | KSP inhibitors of formula I that can be used to treat cellular proliferative disease |
| JP2006515886A (ja) | 2003-01-17 | 2006-06-08 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、および方法 |
| AR050920A1 (es) * | 2003-03-07 | 2006-12-06 | Astrazeneca Ab | Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos |
| PT1601673E (pt) * | 2003-03-07 | 2009-07-29 | Astrazeneca Ab | Heterociclos fundidos e suas utilizações |
| WO2004091547A2 (en) | 2003-04-10 | 2004-10-28 | Cytokinetics, Inc | Compounds, compositions, and methods |
| EP1620092A4 (en) | 2003-05-07 | 2008-04-16 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| WO2005013888A2 (en) | 2003-05-14 | 2005-02-17 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2004103282A2 (en) | 2003-05-15 | 2004-12-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US7022850B2 (en) * | 2003-05-22 | 2006-04-04 | Bristol-Myers Squibb Co. | Bicyclicpyrimidones and their use to treat diseases |
| US7345046B2 (en) * | 2003-05-30 | 2008-03-18 | Chiron Corporation | Heteroaryl-fused pyrimidinyl compounds as anticancer agents |
| ES2339862T3 (es) * | 2003-06-20 | 2010-05-26 | Novartis Vaccines And Diagnostics, Inc. | Compuestos de piridino 1,2-a-pirimidin-4-ona como agentes anticancerosos. |
| JP2007507539A (ja) | 2003-10-06 | 2007-03-29 | サイトキネティクス・インコーポレーテッド | 化合物、組成物及び方法 |
| WO2005046588A2 (en) | 2003-11-07 | 2005-05-26 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| US20050158320A1 (en) * | 2003-11-12 | 2005-07-21 | Nichols M. J. | Combinations for the treatment of proliferative diseases |
| SI1689724T1 (sl) | 2003-11-25 | 2012-04-30 | Novartis Ag | Spojine kinazolinona kot sredstva proti raku |
| EP1692112A4 (en) | 2003-12-08 | 2008-09-24 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS, AND METHODS |
| US7501416B2 (en) * | 2004-02-06 | 2009-03-10 | Bristol-Myers Squibb Company | Quinoxaline compounds and methods of using them |
| ATE419249T1 (de) | 2004-04-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Inhibitoren von mitotischem kinesin |
| DE602005008953D1 (de) | 2004-05-21 | 2008-09-25 | Novartis Vaccines & Diagnostic | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin |
| MXPA06014909A (es) | 2004-06-18 | 2007-02-28 | Chiron Corp | Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer. |
| KR20070046175A (ko) | 2004-08-18 | 2007-05-02 | 아스트라제네카 아베 | 선택된 융합 복소환 및 이의 용도 |
| US20060041128A1 (en) * | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Selected fused heterocyclics and uses thereof |
| EP1807399A2 (en) * | 2004-10-19 | 2007-07-18 | Novartis Vaccines and Diagnostics, Inc. | Indole and benzimidazole derivatives |
-
2005
- 2005-08-16 CN CN2005800282914A patent/CN101027309B/zh not_active Expired - Fee Related
- 2005-08-16 AU AU2005273705A patent/AU2005273705B8/en not_active Ceased
- 2005-08-16 EP EP05771880A patent/EP1781674A1/en not_active Withdrawn
- 2005-08-16 BR BRPI0514390-0A patent/BRPI0514390A/pt not_active IP Right Cessation
- 2005-08-16 KR KR1020077006179A patent/KR20070046176A/ko not_active Ceased
- 2005-08-16 UA UAA200702661A patent/UA89201C2/ru unknown
- 2005-08-16 UY UY29070A patent/UY29070A1/es unknown
- 2005-08-16 MY MYPI20053847A patent/MY141233A/en unknown
- 2005-08-16 US US11/573,683 patent/US20080293744A1/en not_active Abandoned
- 2005-08-16 CA CA002575188A patent/CA2575188A1/en not_active Abandoned
- 2005-08-16 RU RU2007109866/04A patent/RU2447077C2/ru not_active IP Right Cessation
- 2005-08-16 MX MX2007001953A patent/MX2007001953A/es active IP Right Grant
- 2005-08-16 JP JP2007526565A patent/JP2008509977A/ja active Pending
- 2005-08-17 SA SA5260258A patent/SA05260258B1/ar unknown
- 2005-08-18 US US11/207,128 patent/US7498333B2/en not_active Expired - Fee Related
- 2005-08-18 TW TW094128220A patent/TW200616977A/zh unknown
-
2007
- 2007-01-18 IL IL180810A patent/IL180810A0/en unknown
- 2007-02-06 ZA ZA200701082A patent/ZA200701082B/en unknown
- 2007-02-21 NO NO20071005A patent/NO20071005L/no not_active Application Discontinuation
-
2008
- 2008-12-22 US US12/340,855 patent/US20090099210A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200701082B (en) | 2008-07-30 |
| AU2005273705B2 (en) | 2009-12-10 |
| US20090099210A1 (en) | 2009-04-16 |
| CA2575188A1 (en) | 2006-02-23 |
| US20060041129A1 (en) | 2006-02-23 |
| MY141233A (en) | 2010-03-31 |
| TW200616977A (en) | 2006-06-01 |
| EP1781674A1 (en) | 2007-05-09 |
| RU2447077C2 (ru) | 2012-04-10 |
| AU2005273705B8 (en) | 2010-01-28 |
| IL180810A0 (en) | 2007-06-03 |
| AU2005273705A1 (en) | 2006-02-23 |
| JP2008509977A (ja) | 2008-04-03 |
| UY29070A1 (es) | 2006-03-31 |
| US7498333B2 (en) | 2009-03-03 |
| BRPI0514390A (pt) | 2008-06-10 |
| CN101027309A (zh) | 2007-08-29 |
| KR20070046176A (ko) | 2007-05-02 |
| US20080293744A1 (en) | 2008-11-27 |
| UA89201C2 (ru) | 2010-01-11 |
| MX2007001953A (es) | 2007-05-09 |
| SA05260258B1 (ar) | 2009-12-22 |
| RU2007109866A (ru) | 2008-09-27 |
| CN101027309B (zh) | 2010-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20074634L (no) | Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer | |
| NO20063449L (no) | Substituerte heterocykler og deres anvendelse | |
| NO20081893L (no) | 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft | |
| EA202092896A1 (ru) | Гетероциклические и гетероарильные соединения для лечения болезни гентингтона | |
| NO20073791L (no) | Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer | |
| SA521422270B1 (ar) | Apol1 مثبطات لـ وطرق لاستخدامها | |
| EA202092003A1 (ru) | Соединения для лечения болезни гентингтона | |
| WO2018134685A3 (en) | Compounds | |
| EA202092899A1 (ru) | Гетероарильные соединения для лечения болезни гентингтона | |
| NO20081454L (no) | Met-kinaseinhibitorer | |
| EA201370122A1 (ru) | Фармацевтические составы, содержащие ингибиторы деацетилазы гистонов | |
| DK2358717T3 (da) | Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes | |
| NO20080981L (no) | Nitrocatechol-derivater som COMT-inhibitorer | |
| ATE530540T1 (de) | Pyrimidonverbindungen als gsk-3-inhibitoren | |
| NO20081636L (no) | FAP - inhibitorer | |
| NO20061197L (no) | Proteasominhibitorer og fremgangsmater for anvendelse av samme | |
| NO20071521L (no) | Nye fenylaminopyrimidin derivater som hemmere av BCR-ABL kinase | |
| DE60331219D1 (de) | Azaindole als hemmstoffe von c-jun n-terminalen kinasen | |
| NO20062561L (no) | Kinoliner nyttige for behandling av kardiovaskulaere sykdommer | |
| NO20083568L (no) | Hydantoinforbindelser for behandling av inflammatoriske forstyrrelser | |
| EA200870391A1 (ru) | Тетрагидропирролопиримидиндионы и их применение в качестве ингибиторов эластазы нейтрофилов человека | |
| NO20080150L (no) | Inhibitorer av AKT-aktivitet | |
| NO20082673L (no) | Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens | |
| NO20060230L (no) | Nye aminobenzofenonforbindelser | |
| BR112013001632A2 (pt) | composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |